DANVERS, Mass., May 31, 2018 /PRNewswire-PRWeb/ -- Cell Signaling Technology (CST), a leading provider of antibodies,
"A core value of CST has always been innovation and in creating the Innovation and Translational Research Award for Outstanding Scientists of Chinese Heritage, CST hopes that more original research will be transformed into new methods of diagnosis and treatment", said Michael J. Comb, President, and CEO of Cell Signaling Technology. For his outstanding achievements in tumor immunotherapy, as a joint discoverer of the PD-1/PD-L1 pathway and the first to use PD-1 antibodies in cancer treatment clinical trials, Professor Lieping Chen of the Yale University Cancer Center was awarded the inaugural award.
In his speech, Professor Lieping Chen introduced the concept of immunity normalization and said that "immunity normalization shall be a guiding policy for future cancer treatment. Although immunity enhancement is now relatively widespread, this treatment method and its side effects cannot be underestimated."
Speaking at the forum, Jay Dong, Vice President, General Manager Asia Pacific & China, Cell Signaling Technology said "the mission of our generation, and also the intention of this forum and award, is to make the voices of Chinese scientists heard far and wide, and bring together the three sides of scientists, entrepreneurs, and investors, to push forward innovations and transformations for the benefit of mankind."
About CST Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Cell Signaling Technology® and CST™ are trademarks of Cell Signaling Technology, Inc.
SOURCE Cell Signaling Technology
Subscribe to our Free Newsletters!